IVVD — Invivyd, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1832038 ·
Last close
$0.51
Market Cap
$151.09M
52W High
$3.01
52W Low
$0.49
ADV30
4,231,067
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 15,449,000 | 14,406,000 | -34,679,000 | -33,468,000 | 183,905,000 | 126,398,000 | 33,422,000 |
| Jun 2026 | 14,285,000 | 13,012,000 | -45,820,000 | -44,393,000 | 218,883,000 | 160,080,000 | 37,803,000 |
| Mar 2026 | 13,744,000 | 12,712,000 | -43,136,000 | -41,400,000 | 241,742,000 | 184,153,000 | 38,692,000 |
| Dec 2025 | 17,207,000 | 16,067,000 | -12,555,000 | -11,070,000 | 276,883,000 | 226,689,000 | 35,343,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-108,422,000
Investing CF
$-1,236,000
Financing CF
$234,833,000
CapEx
$-1,391,000
Dividends Paid
—
Buybacks
$-231,000
EPS Diluted TTM
$-0.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,040,276,000
Inventory
$310,000
Receivables
$11,683,000
ST Investments
—
EBIT TTM
$-112,534,000
Pretax Income TTM
$-107,333,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$58,365,000
EBITDA
$-111,888,000
Free Cash Flow
$-69,950,752
Enterprise Value
$79,843,992
Total Cash
$160,080,000
Total Debt
$8,391,000
Shares Out
294,758,746
Trailing EPS
$-0.31
Book Value
$0.61
ROE
-95.9%
ROA
-45.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 53,426,000 | -55,560,000 | -52,489,000 | 276,883,000 | 35,343,000 | 241,540,000 | -58,135,000 |
| Dec 2024 | 25,384,000 | -176,876,000 | -169,925,000 | 129,515,000 | 61,976,000 | 67,539,000 | -170,491,000 |
| Dec 2023 | 0 | -207,783,000 | -198,643,000 | 229,181,000 | 51,713,000 | 177,468,000 | -173,164,000 |
| Dec 2022 | 0 | -226,258,000 | -241,317,000 | 383,167,000 | 27,197,000 | 355,970,000 | -219,987,000 |
TTM Snapshot
Revenues TTM
$58,365,000
NetIncome TTM
$-107,333,000
OpCashFlow TTM
—
Assets (Latest)
$218,883,000
Forward EPS
$-0.55
Max Pain — expiry 2026-12-18
max pain strike: $0.50 · spot: $0.47 · call oi: 3,552 · put oi: 886
Expected Move to 2026-12-18:
±$0.16
(32.91%) —
implied range
$0.32 –
$0.63
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IPHA | Innate Pharma SA | $148.56M | $1.33 | — |
| STRO | SUTRO BIOPHARMA, INC. | $148.08M | $8.92 | — |
| HUMA | Humacyte, Inc. | $139.18M | $0.50 | — |
| TARA | Protara Therapeutics, Inc. | $137.10M | $2.32 | — |
| IPHYF | Innate Pharma SA | $168.56M | $1.51 | — |
News headlines (Yahoo Finance, 1h cache)
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
2026-11-16 12:15 · Yahoo
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-16 12:01 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 12:01 · Yahoo
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
2026-10-21 11:01 · Yahoo
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
2026-10-14 11:01 · Yahoo
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
2026-10-05 02:02 · Yahoo
Invivyd’s Covid-directed mAb hits Phase III safety goals
2026-09-30 16:19 · Yahoo
Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
2026-09-29 14:40 · Yahoo
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V
2026-09-29 11:01 · Yahoo
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
2026-09-13 14:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.